{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:35:48Z","timestamp":1761766548048,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.diagmicrobio.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:08:06Z","timestamp":1557360486000},"page":"212-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States \u2014 SMART 2015\u20132017"],"prefix":"10.1016","volume":"95","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle H.","family":"Lob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0005","doi-asserted-by":"crossref","first-page":"e02406","DOI":"10.1128\/AAC.02406-17","article-title":"Inactivation of Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam","volume":"62","author":"Barnes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0010","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0015","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","article-title":"Mutation-driven \u03b2-lactam resistance mechanisms among contemporary ceftazidime-non-susceptible Pseudomonas aeruginosa isolates from U.S. hospitals","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"year":"2013","series-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control & Prevention (CDC)","key":"10.1016\/j.diagmicrobio.2019.05.001_bb0025"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0030","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2018a. 11th edition, M07-A11. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA, USA."},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0035","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 2018b. 28th edition, M100. Clinical and Laboratory Standards Institute, Wayne, PA, USA."},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0045","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant gram-negative bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00169-18","article-title":"In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0055","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jgar.2018.07.012","article-title":"Activity of imipenem-relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions-SMART 2015-2016","volume":"15","author":"Karlowsky","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0065","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase\u2013producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0070","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against Gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0080","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0085","doi-asserted-by":"crossref","first-page":"e02209","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","article-title":"In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 \u2014 results from the SMART global surveillance program","volume":"88","author":"Lob","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2018.05.017","article-title":"Activity of imipenem-relebactam against Gram-negative bacilli from global ICU and non-ICU wards-SMART 2015-2016","volume":"15","author":"Lob","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0100","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1128\/AAC.00338-07","article-title":"Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0105","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0110","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00750-12","article-title":"Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia","volume":"56","author":"Morata","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0115","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17)","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00533-18","article-title":"In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0140","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1128\/AAC.00207-10","article-title":"Impact of multidrug resistant Pseudomonas aeruginosa bacteremia on patient outcomes","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.001_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.diagmicrobio.2017.06.009","article-title":"Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: prevalence and risk factors","volume":"89","author":"Trinh","year":"2017","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319303529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319303529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:53:20Z","timestamp":1760003600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319303529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0732889319303529"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.001","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States \u2014 SMART 2015\u20132017","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}